-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Esperion Therapeutics (NASDAQ:ESPR) Trading Down 5.6%
Esperion Therapeutics (NASDAQ:ESPR) Trading Down 5.6%
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating)'s stock price fell 5.6% during trading on Thursday . The company traded as low as $6.41 and last traded at $6.89. 113,555 shares were traded during mid-day trading, a decline of 93% from the average session volume of 1,687,739 shares. The stock had previously closed at $7.30.
Wall Street Analyst Weigh In
A number of research firms recently commented on ESPR. Morgan Stanley boosted their target price on Esperion Therapeutics from $7.00 to $9.00 and gave the stock an "underweight" rating in a research report on Wednesday, November 2nd. StockNews.com upgraded Esperion Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, November 3rd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $10.17.
Get Esperion Therapeutics alerts:Esperion Therapeutics Trading Down 5.5 %
The firm has a market cap of $508.42 million, a PE ratio of -1.47 and a beta of 0.23. The stock's 50 day moving average price is $6.74 and its 200 day moving average price is $6.96.
Esperion Therapeutics (NASDAQ:ESPR – Get Rating) last posted its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.93) by $0.12. The company had revenue of $18.98 million for the quarter, compared to analyst estimates of $19.83 million. Analysts forecast that Esperion Therapeutics, Inc. will post -3.65 earnings per share for the current year.Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Ikarian Capital LLC acquired a new position in Esperion Therapeutics in the second quarter valued at about $13,067,000. Wasatch Advisors Inc. lifted its holdings in Esperion Therapeutics by 27.6% in the first quarter. Wasatch Advisors Inc. now owns 8,147,380 shares of the biopharmaceutical company's stock valued at $37,804,000 after buying an additional 1,761,117 shares during the period. Millennium Management LLC lifted its holdings in Esperion Therapeutics by 116.8% in the second quarter. Millennium Management LLC now owns 2,706,290 shares of the biopharmaceutical company's stock valued at $17,212,000 after buying an additional 1,457,952 shares during the period. Two Sigma Advisers LP increased its stake in Esperion Therapeutics by 7,991.8% in the third quarter. Two Sigma Advisers LP now owns 1,084,300 shares of the biopharmaceutical company's stock valued at $7,265,000 after purchasing an additional 1,070,900 shares in the last quarter. Finally, Woodline Partners LP bought a new stake in Esperion Therapeutics in the second quarter valued at approximately $5,372,000. Institutional investors own 85.87% of the company's stock.
Esperion Therapeutics Company Profile
(Get Rating)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
Read More
- Get a free copy of the StockNews.com research report on Esperion Therapeutics (ESPR)
- Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
- Is Wendy's Stock Uptrend Set To Continue?
- Altria Group Stock, Is Time is Running Out?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating)'s stock price fell 5.6% during trading on Thursday . The company traded as low as $6.41 and last traded at $6.89. 113,555 shares were traded during mid-day trading, a decline of 93% from the average session volume of 1,687,739 shares. The stock had previously closed at $7.30.
艾斯佩里昂治療有限公司(NASDAQ:ESPR-獲得評級)的股價在周四交易期間下跌了 5.6%。該公司的交易價格低至 6.41 美元,最後交易價格為 6.89 美元。在日中交易期間交易了 113,555 股,較 1,687,739 股的平均交易量下降了 93%。該股票之前已收盤 7.30 美元。
Wall Street Analyst Weigh In
華爾街分析師稱重
A number of research firms recently commented on ESPR. Morgan Stanley boosted their target price on Esperion Therapeutics from $7.00 to $9.00 and gave the stock an "underweight" rating in a research report on Wednesday, November 2nd. StockNews.com upgraded Esperion Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, November 3rd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $10.17.
一些研究公司最近對 ESPR 進行了評論。摩根士丹利將 Esperion 治療的目標價格從 7.00 美元提高到 9.00 美元,並在 11 月 2 日(週三)的一份研究報告中給予該股「體重不足」評級。在 11 月 3 日(星期四)的報告中,Stocknews.com 將埃斯佩里昂治療從「賣出」評級升級為「持有」評級。兩位投資分析師對該股票進行了賣出評級,其中兩人給予持有評級,另一位則為該公司的股票分配了買入評級。根據 MarketBeat.com 的數據,該公司目前的共識評級為「持有」,平均價格目標為 10.17 美元。
Esperion Therapeutics Trading Down 5.5 %
艾斯佩里昂治療學交易下降 5.5%
The firm has a market cap of $508.42 million, a PE ratio of -1.47 and a beta of 0.23. The stock's 50 day moving average price is $6.74 and its 200 day moving average price is $6.96.
該公司的市值為 50842 萬美元,私募股權比率為 -1.47,貝塔值為 0.23。該股票的 50 日移動平均價格為 6.74 美元,其 200 日移動平均價格為 6.96 美元。
Institutional Inflows and Outflows
機構流入和流出
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Ikarian Capital LLC acquired a new position in Esperion Therapeutics in the second quarter valued at about $13,067,000. Wasatch Advisors Inc. lifted its holdings in Esperion Therapeutics by 27.6% in the first quarter. Wasatch Advisors Inc. now owns 8,147,380 shares of the biopharmaceutical company's stock valued at $37,804,000 after buying an additional 1,761,117 shares during the period. Millennium Management LLC lifted its holdings in Esperion Therapeutics by 116.8% in the second quarter. Millennium Management LLC now owns 2,706,290 shares of the biopharmaceutical company's stock valued at $17,212,000 after buying an additional 1,457,952 shares during the period. Two Sigma Advisers LP increased its stake in Esperion Therapeutics by 7,991.8% in the third quarter. Two Sigma Advisers LP now owns 1,084,300 shares of the biopharmaceutical company's stock valued at $7,265,000 after purchasing an additional 1,070,900 shares in the last quarter. Finally, Woodline Partners LP bought a new stake in Esperion Therapeutics in the second quarter valued at approximately $5,372,000. Institutional investors own 85.87% of the company's stock.
一些機構投資者和對沖基金最近更改了他們在股票中的頭寸。伊卡利資本有限責任公司在第二季度收購了埃斯佩里昂治療學的新職位,價值約為 13,067,000 美元。瓦薩奇顧問公司在第一季度取消了其在埃斯佩里昂治療學的持有 27.6%。在期內額外購買 1,761,117 股股票後,瓦沙奇顧問公司現在擁有該生物製藥公司股票的 8,147,380 股價值 37,804,000 美元。千禧管理有限責任公司在第二季度取消了其在埃斯佩里昂治療的控股 116.8%.千禧管理有限責任公司現在擁有該生物製藥公司的 2706,290 股股份,價值為 17,212,000 美元,在此期間額外購買了 1,457,952 股股份。兩個西格瑪顧問 LP 增加了其在埃斯佩里昂治療的股份 7,991.8% 在第三季度.兩位西格瑪顧問 LP 現在擁有該生物製藥公司的 1,084,300 股股票,價值 7,265,000 美元,在上個季度購買了 1,070,900 股股票。最後, 伍德林合作夥伴 LP 在第二季度買了一個新的股份,價值約為 $5,372,000.機構投資者擁有該公司股票的 85.87%。
Esperion Therapeutics Company Profile
艾斯佩利昂治療公司簡介
(Get Rating)
(取得評分)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
Esperion Theraptics, Inc. 是一家製藥公司,開發和商業化用於治療低密度脂蛋白膽固醇升高患者的藥物。其主要候選產品是 NEXLETOL(貝苯二酸)和 NEXLIZET(貝西多酸和以西咪)片劑,用於治療動脈粥樣硬化心血管疾病或雜合子家族高膽固醇血症患者。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Esperion Therapeutics (ESPR)
- Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
- Is Wendy's Stock Uptrend Set To Continue?
- Altria Group Stock, Is Time is Running Out?
- 獲取有關艾斯佩里昂治療學(ESPR)的研究報告的免費副本
- 索倫托治療學,希雷克斯:移動中的 2 熱製藥股票
- 阿里巴巴大復甦即將開始嗎?
- KB 首頁, 另一個原因擺脫家庭建築股票
- 溫迪的股票上漲趨勢將繼續嗎?
- 奧特利亞集團股票,時間已經不多了嗎?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收艾斯佩里昂治療的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Esperion 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧